hydroxyurea has been researched along with Vascular Diseases in 30 studies
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Growing considerations for this population in the literature include cutaneous reactions to common treatments such as hydroxyurea and clinical management of the intersection between sickle cell disease and conditions like plaque psoriasis." | 5.41 | Cutaneous manifestations of sickle cell disease: an updated review. ( Dick, A; Khachemoune, A; Schwartzman, G, 2023) |
| "Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated primarily with analgesics for pain relief." | 4.93 | Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. ( Telen, MJ, 2016) |
| "The complex pathophysiology of sickle cell anemia (SCA) involves intravascular hemolytic processes and recurrent vaso-occlusion, driven by chronic vascular inflammation, which result in the disease's severe clinical complications, including recurrent painful vaso-occlusive episodes." | 1.56 | Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies. ( Almeida, CB; Brito, PL; Brockschnieder, D; Chweih, H; Conran, N; Costa, FF; Ferreira, WA; Franco-Penteado, CF; Frenette, PS; Garcia, F; Gotardo, EMF; Lanaro, C; Leonardo, FC; Miguel, LI; Saad, STO; Sandner, P; Stasch, JP; Torres, L, 2020) |
| "Hydroxyurea therapy was used in 30 patients (31." | 1.36 | Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management. ( Cotton, F; Dedeken, L; Dresse, MF; Ferster, A; Gulbis, B; Heijmans, C; Ketelslegers, O; Lê, PQ; Vanderfaeillie, A; Vermylen, C; Vertongen, F, 2010) |
| "Hydroxyurea treatment, as well as and long- and short-acting narcotics were given, with little improvement in symptoms." | 1.33 | Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease. ( Abish, S; Albuquerque, P; Alyaarubi, S; Gale, M; Jabado, N; Krishnamoorthy, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 15 (50.00) | 24.3611 |
| 2020's | 6 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dick, A | 3 |
| Schwartzman, G | 3 |
| Khachemoune, A | 3 |
| Fogarty, H | 1 |
| Ahmad, A | 1 |
| Atiq, F | 1 |
| Doherty, D | 1 |
| Ward, S | 1 |
| Karampini, E | 1 |
| Rehill, A | 1 |
| Leon, G | 1 |
| Byrne, C | 1 |
| Geoghegan, R | 1 |
| Conroy, H | 1 |
| Byrne, M | 1 |
| Budde, U | 1 |
| Schneppenheim, S | 1 |
| Sheehan, C | 1 |
| Ngwenya, N | 1 |
| Baker, RI | 1 |
| Preston, RJS | 1 |
| Tuohy, E | 1 |
| McMahon, C | 1 |
| O'Donnell, JS | 1 |
| Chouhan, U | 1 |
| Janghel, T | 1 |
| Bhatt, S | 1 |
| Kurmi, S | 1 |
| Choudhari, JK | 1 |
| Lim, SH | 1 |
| Dutta, D | 1 |
| Moore, J | 1 |
| Barbu, EA | 1 |
| Mendelsohn, L | 1 |
| Samsel, L | 1 |
| Thein, SL | 1 |
| White, J | 1 |
| Lancelot, M | 1 |
| Gao, X | 1 |
| McGraw, BJ | 1 |
| Tabb, C | 1 |
| Hines, P | 1 |
| Ferreira, WA | 1 |
| Chweih, H | 1 |
| Lanaro, C | 1 |
| Almeida, CB | 2 |
| Brito, PL | 1 |
| Gotardo, EMF | 1 |
| Torres, L | 1 |
| Miguel, LI | 1 |
| Franco-Penteado, CF | 1 |
| Leonardo, FC | 1 |
| Garcia, F | 1 |
| Saad, STO | 1 |
| Frenette, PS | 4 |
| Brockschnieder, D | 1 |
| Costa, FF | 2 |
| Stasch, JP | 1 |
| Sandner, P | 1 |
| Conran, N | 2 |
| Teixeira, RS | 1 |
| Terse-Ramos, R | 1 |
| Ferreira, TA | 1 |
| Machado, VR | 1 |
| Perdiz, MI | 1 |
| Lyra, IM | 1 |
| Nascimento, VL | 1 |
| Boa-Sorte, N | 1 |
| Andrade, BB | 1 |
| Ladeia, AM | 1 |
| Sharef, SW | 1 |
| Al-Hajri, M | 1 |
| Beshlawi, I | 1 |
| Al-Shahrabally, A | 1 |
| Elshinawy, M | 1 |
| Zachariah, M | 1 |
| Mevada, ST | 1 |
| Bashir, W | 1 |
| Rawas, A | 1 |
| Taqi, A | 1 |
| Al-Lamki, Z | 1 |
| Wali, Y | 1 |
| Keikhaei, B | 1 |
| Mohseni, AR | 1 |
| Norouzirad, R | 1 |
| Alinejadi, M | 1 |
| Ghanbari, S | 1 |
| Shiravi, F | 1 |
| Solgi, G | 1 |
| Manwani, D | 2 |
| Oberoi, S | 1 |
| Das, R | 1 |
| Trehan, A | 1 |
| Ahluwalia, J | 1 |
| Bansal, D | 1 |
| Malhotra, P | 1 |
| Marwaha, RK | 1 |
| Sarray, S | 1 |
| Saleh, LR | 1 |
| Lisa Saldanha, F | 1 |
| Al-Habboubi, HH | 1 |
| Mahdi, N | 1 |
| Almawi, WY | 1 |
| Barazia, A | 1 |
| Li, J | 1 |
| Kim, K | 1 |
| Shabrani, N | 1 |
| Cho, J | 1 |
| Telen, MJ | 1 |
| Olnes, M | 1 |
| Chi, A | 1 |
| Haney, C | 1 |
| May, R | 1 |
| Minniti, C | 1 |
| Taylor, J | 1 |
| Kato, GJ | 1 |
| Candrilli, SD | 1 |
| O'Brien, SH | 1 |
| Ware, RE | 1 |
| Nahata, MC | 1 |
| Seiber, EE | 1 |
| Balkrishnan, R | 1 |
| Lê, PQ | 1 |
| Ferster, A | 2 |
| Cotton, F | 1 |
| Vertongen, F | 1 |
| Vermylen, C | 1 |
| Vanderfaeillie, A | 1 |
| Dedeken, L | 1 |
| Heijmans, C | 1 |
| Ketelslegers, O | 1 |
| Dresse, MF | 1 |
| Gulbis, B | 1 |
| Smith, WR | 1 |
| Scheiermann, C | 1 |
| Jang, JE | 1 |
| Prophete, C | 1 |
| El Nemer, W | 1 |
| Amrolia, PJ | 1 |
| Almeida, A | 1 |
| Davies, SC | 1 |
| Roberts, IA | 1 |
| Al-Zahrani, H | 1 |
| Gupta, V | 1 |
| Minden, MD | 1 |
| Messner, HA | 1 |
| Lipton, JH | 1 |
| Krishnamoorthy, P | 1 |
| Alyaarubi, S | 1 |
| Abish, S | 1 |
| Gale, M | 1 |
| Albuquerque, P | 1 |
| Jabado, N | 1 |
| Finnegan, EM | 1 |
| Turhan, A | 1 |
| Golan, DE | 1 |
| Barabino, GA | 1 |
| Couillard, S | 1 |
| Benkerrou, M | 1 |
| Girot, R | 1 |
| Brousse, V | 1 |
| Bader-Meunier, B | 1 |
| Boivin, P | 1 |
| Najean, Y | 1 |
| Rain, JD | 1 |
| Bégué, P | 1 |
| Castello-Herbreteau, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain[NCT01757418] | Phase 1/Phase 2 | 300 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
| Studies of the Natural History of Sickle Cell Disease[NCT00081523] | 3,500 participants (Anticipated) | Observational | 2004-04-29 | Recruiting | |||
| Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082] | 64 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease[NCT02824471] | 100 participants (Anticipated) | Observational | 2014-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for hydroxyurea and Vascular Diseases
| Article | Year |
|---|---|
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Vascular Diseases | 2013 |
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.
Topics: Analgesics; Anemia, Sickle Cell; Animals; Antisickling Agents; Blood Coagulation; Cell Adhesion; Dru | 2016 |
Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Central Nervous System Diseas | 2003 |
Vascular events associated with alpha interferon therapy.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Foot Ulcer; Gangrene; Hemolytic-Uremic Syndrome | 2003 |
[Sickle cell disease: from childhood to adolescence. Management in 2001].
Topics: Acute Disease; Adolescent; Anemia, Sickle Cell; Bacterial Infections; Child; Humans; Hydroxyurea; In | 2001 |
4 trials available for hydroxyurea and Vascular Diseases
| Article | Year |
|---|---|
Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Hemoglobins; | 2013 |
Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Arginase; Blood Pressure; Disease-Free Survival; Ec | 2009 |
Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Topics: Acute Disease; Bloodletting; Combined Modality Therapy; Humans; Hydroxyurea; Leukemia; Phosphorus Ra | 1993 |
Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
Topics: Actuarial Analysis; Aged; Alkylating Agents; Combined Modality Therapy; Disease Progression; Follow- | 1997 |
20 other studies available for hydroxyurea and Vascular Diseases
| Article | Year |
|---|---|
VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.
Topics: ADAMTS13 Protein; Anemia, Sickle Cell; Blood Transfusion; Child; Hemolysis; Hemostatics; Humans; Hyd | 2023 |
New Insights into Clinical Management for Sickle Cell Disease: Uncovering the Significant Pathways Affected by the Involvement of Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Antiviral Agents; Blood Transfusion; Child; Erythrocytes; Humans; Hydroxyurea; | 2024 |
Rifaximin for sickle cell disease.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents; beta-Thalassemia; Cellular Se | 2019 |
Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises.
Topics: Adult; Anemia, Sickle Cell; Cohort Studies; Cytokines; Extracellular Traps; Female; Humans; Hydroxyu | 2020 |
Cross-sectional analysis of adhesion in individuals with sickle cell disease using a standardized whole blood adhesion bioassay to VCAM-1.
Topics: Adult; Anemia, Sickle Cell; Biological Assay; Blood Cell Count; Cell Adhesion; Cross-Sectional Studi | 2020 |
Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies.
Topics: Anemia, Sickle Cell; Animals; Benzoates; Biphenyl Compounds; Cell Line, Tumor; Disease Models, Anima | 2020 |
Associations between endothelial dysfunction and clinical and laboratory parameters in children and adolescents with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bilirubin; C-Reactive Protein; Case-Control St | 2017 |
Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Case-Control Studies; Cytokines; Demography; Female; Humans; | 2013 |
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion; Endothelium, Vascular; Humans; Hydroxyurea; | 2013 |
HbSD-Punjab: clinical and hematological profile of a rare hemoglobinopathy.
Topics: Acute Chest Syndrome; Anemia; Antisickling Agents; Child; Child, Preschool; Chromatography, High Pre | 2014 |
Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Infant | 2015 |
Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice.
Topics: Anemia, Sickle Cell; Animals; E-Selectin; Hydroxyurea; Intercellular Adhesion Molecule-1; Mice; Phos | 2015 |
Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Data Collection; Drug Evaluation; Emergencies; Female | 2011 |
Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Antisickling Agents; Belgium; Bone Marrow Transplantation; | 2010 |
Pain in sickle cell disease: the future of acute treatment.
Topics: Acute Disease; Anemia, Sickle Cell; Biomarkers; Humans; Hydroxyurea; Pain; Vascular Diseases | 2011 |
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Anemia, Sickle Cell; Animals; Antisickling Agent | 2012 |
HU for acute treatment of sickle VOC?
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Cyclic GMP; Female; Humans; Hydroxyurea; Male; Py | 2012 |
Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease.
Topics: Adenoma; Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Arthralgia; Back Pain; Bone Resorption | 2006 |
Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion; Endothelial Cells; Erythrocytes, Abnormal; | 2007 |
Steroid treatment in children with sickle-cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Arthritis; Autoimmune Diseases; Blood Transfusion; Child; Child, Pr | 2007 |